This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Moran, S. V Articles by Flaskamp, R. Search for Related Content PubMed PubMed Citation Articles by Moran, S. V Articles by Flaskamp, R. Social Bookmarking                   What's this?

Comparison of two doses of aprotinin in patients receiving aspirin before coronary bypass surgery

Departments of Cardiovascular Diseases and Anaesthesia, Catholic University of Chile, smoran{at}med.puc.cl

Guillermo Lema

Departments of Cardiovascular Diseases and Anaesthesia, Catholic University of Chile

Jessica Medel

Departments of Cardiovascular Diseases and Anaesthesia, Catholic University of Chile

Manuel J Irarrazaval

Departments of Cardiovascular Diseases and Anaesthesia, Catholic University of Chile

Ricardo Zalaquett

Departments of Cardiovascular Diseases and Anaesthesia, Catholic University of Chile

Bernardita Garayar

Departments of Cardiovascular Diseases and Anaesthesia, Catholic University of Chile

Renate Flaskamp

Bayer Laboratories, Chile

This study was designed to evaluate efficacy and tolerability of two different doses of aprotinin in patients receiving aspirin before undergoing coronary artery bypass grafting. Forty-two patients were randomized to receive either placebo (group I), or aprotinin in doses of 4 000 000 KIU (group II) or 6 000 000 KIU (group III). Drug efficacy was determined by measuring postoperative blood loss and transfusion of blood products. Both doses were effective in reducing blood loss and transfusion requirements. Blood loss through thoracotomy drainage was 450 ± 224, 182 ± 144, 142 ± 98 ml, respectively, for control and treatment groups II and III (p = 0.0001). The numbers of patients with blood transfusions were seven (50%), two (17%) and two (17%) for group I and treatment groups II and III, respectively (p = 0.10). Tolerability was excellent and complications few and reversible.

In conclusion, high and medium doses of aprotinin were well tolerated and reduced bleeding and transfusion requirements in patients submitted to coronary bypass surgery under the effects of aspirin.

Perfusion, Vol. 15, No. 2, 105-110 (2000)
DOI: 10.1177/026765910001500204


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D. R. McIlroy, P. S. Myles, L. E. Phillips, and J. A. Smith Antifibrinolytics in cardiac surgical patients receiving aspirin: a systematic review and meta-analysis Br. J. Anaesth., February 1, 2009; 102(2): 168 - 178. [Abstract] [Full Text] [PDF]

				J. R. Brown, N. J.O. Birkmeyer, and G. T. O'Connor Meta-Analysis Comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery Circulation, June 5, 2007; 115(22): 2801 - 2813. [Abstract] [Full Text] [PDF]

				A. Ronald and J. Dunning Does use of aprotinin decrease the incidence of stroke and neurological complications in adult patients undergoing cardiac surgery? Interactive CardioVascular and Thoracic Surgery, December 1, 2006; 5(6): 767 - 773. [Abstract] [Full Text] [PDF]

				A. Sedrakyan, T. Treasure, and J. A. Elefteriades Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: A systematic review and meta-analysis of randomized clinical trials J. Thorac. Cardiovasc. Surg., September 1, 2004; 128(3): 442 - 448. [Abstract] [Full Text] [PDF]